自身免疫性肝炎诊断与管理中的无创生物标志物
本文综述了成人和儿童自身免疫性肝炎(AIH)不同阶段的新型候选生物标志物,涵盖基因表达谱、蛋白质、代谢物和免疫细胞表型,并讨论了其他免疫疾病中相关的生物标志物。文章指出,能够预测疾病临床病程、识别高复发风险患者并改进监测和用药剂量的生物标志物具有很高的临床价值,最后提出了将生物标志物应用于临床实践以推进AIH个性化治疗的未来方向。
要点
- AIH一线治疗为全身性糖皮质激素或布地奈德联合硫唑嘌呤,多数患者初始有应答,但缺乏应答预测因素。
- 复发非常常见,与组织学活动度相关(即使血清转氨酶正常),并增加肝纤维化。
- 能预测临床病程、识别复发高风险、改进监测和用药剂量的生物标志物具有高临床价值。
核心结论
- 本综述基于预设标准回顾了成人和儿童AIH不同阶段的新型候选生物标志物,并提出了将生物标志物应用于临床实践以推进AIH个性化治疗的未来方向。
研究设计与样本
- 综述类:文章基于预设标准回顾了成人和儿童AIH不同阶段的新型候选生物标志物,包括基因表达谱、蛋白质、代谢物和免疫细胞表型,并讨论了其他免疫疾病中与AIH相关的生物标志物。
主要发现
- AIH是一种病因不明的罕见疾病,以自身耐受丧失为特征,可导致肝损伤、肝硬化和急性肝衰竭。
- 一线治疗由全身性糖皮质激素或布地奈德联合硫唑嘌呤组成,大多数患者初始有应答,但缺乏应答预测因素。
- 复发非常常见,与组织学活动度相关(尽管血清转氨酶正常),并增加肝纤维化。
- 当前治疗方案导致不良反应和生活质量下降,而药物滴定不精确。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune hepatitis (AIH) is a rare disease of unclear etiology characterized by loss of self-tolerance that can lead to liver injury, cirrhosis, and acute liver failure. First-line treatment consists of systemic corticosteroids, or budesonide, and azathioprine, to which most patients are initially responsive, although predictors of response are lacking. Relapses are very common, correlate with histological activity despite normal serum transaminases, and increase hepatic fibrosis. Furthermore, current regimens lead to adverse effects and reduced quality of life, whereas medication titration is imprecise. Biomarkers that can predict the clinical course of disease, identify patients at elevated risk for relapse, and improve monitoring and medication dosing beyond current practice would have high clinical value. Herein, we review novel candidate biomarkers in adult and pediatric AIH based on prespecified criteria, including gene expression profiles, proteins, metabolites, and immune cell phenotypes in different stages of AIH. We also discuss biomarkers relevant to AIH from other immune diseases. We conclude with proposed future directions in which biomarker implementation into clinical practice could lead to advances in personalized therapeutic management of AIH.
引用
- Harrington C, Krishnan S, Mack CL, et al. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology. 2022. PMID: 35611859. doi:10.1002/hep.32591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。